前房增殖膜拦截(AC-PMI)增强小梁切除术与传统小梁切除术治疗新生血管性青光眼:随机对照试验方案
本研究为单中心、前瞻性、双臂、优效性随机对照试验,拟纳入100例新生血管性青光眼住院患者,随机分为传统小梁切除术组(术前抗血管内皮生长因子、术中丝裂霉素C)与前房增殖膜拦截(AC-PMI)增强小梁切除术组(同样用药),随访至术后24个月,评估疗效与安全性。
要点
- AC-PMI增强小梁切除术是在传统滤过手术基础上增加拦截增殖膜步骤,以阻止纤维血管组织生长。
- 研究纳入100例新生血管性青光眼住院患者,随机分为AC-PMI增强组与传统小梁切除术组。
- 两组均术前使用抗血管内皮生长因子、术中使用丝裂霉素C,随访至术后24个月。
核心结论
- 研究旨在评估AC-PMI增强小梁切除术相较于传统小梁切除术治疗新生血管性青光眼的疗效与安全性。
研究设计与样本
- 单中心、前瞻性、双臂、优效性随机对照试验,拟纳入100例新生血管性青光眼住院患者。
- 采用随机数字表法将患者随机分入两组。
- 一组行传统小梁切除术,术前使用抗血管内皮生长因子、术中应用丝裂霉素C。
- 另一组行AC-PMI增强小梁切除术,同样术前使用抗血管内皮生长因子、术中应用丝裂霉素C。
- 随访时间点为基线及术后1天、1周、1个月、3个月、6个月、12个月、18个月、24个月。
主要发现
- 本研究为试验方案,尚未报告疗效或安全性结果。
关键数值与推荐
- 试验注册号ChiCTR2200055138,注册日期2022年1月1日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neovascular glaucoma (NVG) is an irreversible blinding eye disease worldwide and is classified as one of the refractory glaucoma conditions, severely impacting visual function and vision. Unfortunately, effective surgical interventions to improve the prognosis of NVG patients are currently lacking. The study aims to evaluate the efficacy and safety of anterior chamber proliferative membrane interception (AC-PMI)-enhanced trabeculectomy compared to the traditional trabeculectomy. METHODS: AC-PMI enhanced trabeculectomy versus trabeculectomy for the treatment of NVG is a single-center, prospective, double-arms, and randomized controlled trial of superior efficacy, which will involve 100 NVG inpatients. Patients will be randomly assigned into two groups using the random number table method. One group will undergo trabeculectomy using anti-vascular endothelial growth factor (Anti-VEGF) preoperatively and mitomycin C intraoperatively, while the other group will undergo AC-PMI enhanced trabeculectomy with the same medications (Anti-VEGF and mitomycin C). The patients will be followed up at the baseline and 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months postoperatively. Meanwhile, we will collect the demographics, characteristics, and examination results and monitor any occurrences of adverse events at each follow-up time. DISCUSSION: This is an efficacy study of a novel surgical approach for treating neovascular glaucoma. Building upon conventional filtering surgeries, this approach introduces an additional step involving the interception of the proliferative membrane to effectively halt the growth of fibrovascular tissue. This study aims to explore a promising new surgical approach for managing NVG and contribute to the advancement of glaucoma treatment strategies. TRIAL REGISTRATION: ChiCTR ChiCTR2200055138. Registered on 01 January 2022. https://www.chictr.org.cn/showproj.html?proj=145255.
引用
- Zhu S, Zhou M, Li H, et al. Anterior chamber proliferative membrane interception (AC-PMI)-enhanced trabeculectomy versus trabeculectomy for treating neovascular glaucoma: protocol for a randomized controlled trial. Trials. 2024. PMID: 38679725. doi:10.1186/s13063-024-08123-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。